Hereditary Papillary Renal Carcinoma

What Causes Kidney Cancer?
What Causes Kidney Cancer? administrator 4 Views • 2 years ago

Transcript:

What Causes Kidney Cancer?

Kidney cancer causes are unclear. At this point medical researchers have only been able to learn that kidney cancer begins much in the same way as other cancers begin: through DNA mutations. These mutations program the cells to grow and divide abnormally, forming a tumor. The cells can also spread to other parts of the body (a process known as metastasis).

A type of kidney cancer known as renal cell carcinoma is the most common variety in adults. A number of others are less common, including transitional cell carcinoma, which can begin in the kidneys but can affect the ureters. A condition known as Wilms tumor is the most common cause of kidney cancer in children.

While precise causes have been difficult to isolate, researchers have been able to discover that there are certain risk factors for kidney cancer that seem to make development more likely. It's probably not a coincidence that these possible kidney cancer causes are similar to causes that are often connected to other types of cancer.

As you get older, especially past age 65, your odds of getting kidney cancer increase.

Smokers have a higher chance of getting kidney cancer than nonsmokers do. If you quit, your chances go down.

People who are grossly overweight or morbidly obese are more likely to get kidney cancer.

High blood pressure increases your risk of kidney cancer. High blood pressure and diabetes are both extremely dangerous for those with kidney disease, but the exact connection between hypertension and kidney cancer is unclear.

Kidney failure also appears to be one of the causes of kidney cancer. Individuals who receive kidney dialysis treatments for renal insufficiency or chronic kidney failure develop kidney cancer at a higher rate than those who don't.

Hereditary factors may also play a role. People with an inherited disorder known as Von Hippel-Lindau disease seem to be prone to developing several kinds of tumors, including kidney cancer. There's also a condition known as hereditary papillary renal cell carcinoma that appears to be one of the kidney cancer causes.

Gender may be important. Statistically, more men develop kidney cancer than women.

Certain non-medical factors may helps cause kidney cancer. Environmental factors, like certain kinds of chemicals in your workplace may put you in a higher risk group. Research seems to indicate that people who work around asbestos and cadmium have higher kidney cancer rates than the normal population.

There are a number of kidney tests available to detect kidney cancer and other types of kidney problems. One method employs ultrasound to generate images of the kidneys. CT and MRI scans are other popular diagnostic tools.

Kidney cancer causes few symptoms until it progresses to a later stage. When symptoms of kidney cancer begin to appear, they're likely to include

a dark, cloudy, or even red-tinged urine stream (indicating blood in urine),
back pain in the flank region, just below the ribs,
unexplained weight loss,
fatigue and difficulty concentrating
fever, vomiting and nausea.

If you have any of these symptoms, it is important to see your medical professional as soon as you can. Your doctor will run kidney tests and use other diagnostic tools to see if you have kidney problems. Once again, the sooner kidney cancer is detected, the more likely it is there will be a happy outcome.

The incidence of kidney cancer seems to be increasing. More than 50,000 individuals are diagnosed with kidney cancer each year and this number is growing, though it isn't clear why. The death rate for kidney cancer is approximately 12,000 persons annually in the United States.

Cracking the Code for Improved Patient Outcomes in Advanced Renal Cell Carcinoma
Cracking the Code for Improved Patient Outcomes in Advanced Renal Cell Carcinoma administrator 3 Views • 2 years ago

To claim CME please visit this link: http://bit.ly/3YQqiXv

.75 CME | MOC

In this case based discussion, discover recent clinical trial findings on checkpoint inhibitors and VEGFR-directed therapies that can inform personalized care plans for patients with renal cell carcinoma (RCC). Dr. Eric Jonasch, Professor in the Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center, will provide expert perspectives on the myriad of novel therapeutic options for advanced RCC. Start the activity now!

STATEMENT OF NEED
Renal cell carcinoma (RCC) comprises 2.4% of malignancies in adults worldwide (Makino et al, 2022). It is estimated that 79,000 new cases of kidney cancer were diagnosed in the US in 2022 (Siegel et al, 2022). RCC is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. Several new therapies have been approved for RCC in recent years; therefore, it is important for the cancer care team to update their knowledge of RCC pathophysiology and the benefits and risks of novel therapies. In this activity presented at the Society of Government Service Urologists James C. Kimbrough Urological Seminar, Eric Jonasch, MD, Professor in the Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center, imparts expert perspectives and details the latest treatment options for advanced RCC.

TARGET AUDIENCE
Military, academic, and private practice urologists, nurse practitioners, and physician assistants involved in the treatment of patients with renal cell carcinoma.

LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:

Discuss the immunogenicity of RCC and the implications for the treatment of advanced disease
Assess criteria for risk stratification of patients with advanced RCC
Evaluate recent clinical trial findings on novel treatment strategies for advanced RCC with checkpoint inhibitors and VEGFR-directed therapies

Renal Cell Carcinoma for USMLE
Renal Cell Carcinoma for USMLE administrator 2 Views • 2 years ago

Renal Cell Carcinoma Anatomy, Epidemiology, Etiology, Clinical Signs and Symptoms, Treatment and Management. Handwritten, full lecture for medical students taking USMLE.

Renal Cell Carcinomas make up 90-95% of kidney neoplasms.

ETIOLOGY of Renal Cell Carcinoma
Smoking is the largest risk factor. Obesity and Hyppertension is a known risk factor for Renal Cell Carcinoma in Women. Occupational Exposure such as Trichloroethylene, Benzine, Herbicides, Vinyl Chloride. Drugs associated with Renal Cell Carcinoma (phenacitin). Long term dialysis increases the risk of cystic Diseases which increase risk of renal cell carcinoma.

Von Hipel Lindau - Loss of 3p increases HIF which increases angiogenesis. Also increase risk of pheochromocytoma, pancreatic cysts/islet cell tumors, retinal angiomas, CNS hemangioblastomas.

Hereditary Papillary Renal Carcinoma - MET Gene mutation of tyrosine kinase domain and will have bilateral multifocal papillary renal cell carcinoma.

Burt-Hogg-Dube Syndrome - Bilateral Multifocal oncocytoma which has a better prognosis. Also may cause pulmonary and colonic tumors.

CLINICAL SIGNS AND SYMPTOMS of Renal Cell Carcinoma.
The three most common presenting signs and symptoms is flank pain, hematuria, flank mass. A large percentage of patients may be asymptomatic. Patients with renal cell carcinoma may also have wieght loss, varicocele, malaise, fever.

Paraneoplastic syndromes are very common in renal cell carcinoma. Increase EPO may lead to polycythemia, Renin production may lead to hypetension. Finally may also have hypercalcemia, polyneuropathy.

Shauffer Syndrome - Non-metastatic Hepatic Dysfunction and therefore it is important to monitor liver function, even if no metastasis has occurred.

Metastasis to Lungs (45%), Soft tissue and Liver.

Work Up for Renal Cell carcinoma
Labs - Urinalysis, CBC, Electrolytes, Renal Profile, LFT (AST/ALT) and Serum Calcium.

Imaging - CT scan is the imaging of choice and can identify the tumor and rule out cystic mass. Also allows visualtion of Lymph nodes, Renal Vein, IVC and helps rule out angiolipoma.

For staging abdominal ;pelvic CT with or without contrast. Chest X-ray and Brain MRI.

Histology
Clear Cell Carcinoma - 75%, lipid/glycogen
Chromphilic - Bilateral mulftifocal
Chromophobic - Large polygonal Cells
Oncocytoma - Rarely metastasize
Collecting Tubules

STAGING OF Renal Cell Carcinoma
Stage 1 - Within the kidney and less than 7cm.
Stage 2 - Within the kidney and greater than 7cm.
Stage 3 - Invasion Renal Vein and Inferior Vena Cava or Adrenal Gland, but does not invade Gerota's Fascia
Stage 4 - Extends below Gerota's Fascia, invade nearby lymph nodes and metastasis to organs.

MANAGEMENT of Renal Cell Carcinoma
Surgical
Partial nephrectomy for stage 1 and sometimes stage 2
Radical Nephrectomy - remove complete removal of Gerota's fascia, Removal of kidney with adrenal gland, dissect enlarge lymph nodes.
Palliative Nephrectomy - remove kidney to alleviate pain, polycythemia and hypertension.

Adjuvant Treatment for Renal Cell Carcinoma
Biologic Response Mediators - IL2 (activates T Cell and NK), IFN
Molecular Targeting - Suritinib, Bevacizumab, Dazopomib, Temsirolimu, Sorafenib.

Chemotherapy - 5 floururacil, Vinblastine, Paclitaxel, Caboplatin, Ifosfamide, Gemcitabine.

Radiation - Renal Cell Carcinoma is not sensitive to radiation but the brain metastasize are sensitive.

Renal Artery Embolization inject ethanol or gelatin sponge pledgets in artery feeding tumor to help kill off the tumor. Also done palliative for non-surgical patient.

Papillary renal cell carcinoma - Medical Definition
Papillary renal cell carcinoma - Medical Definition administrator 1 Views • 2 years ago

https://word2speech.com/medical/

Papillary renal cell carcinoma

Papillary renal cell carcinoma: A type of kidney cancer that accounts for 15 to 20% of renal carcinomas. It occurs in both sporadic and familial forms. Hereditary papillary renal carcinoma is characterized by the development of multiple papillary tumors in both kidneys. The pattern of inheritance is consistent with autosomal dominant transmission with reduced penetrance. The disorder is distinct from other forms of inherited kidney cancer.

How to pronounce, definition of, audio dictionary, medical dictionary

Rare Cancer Meta-Analysis, pt.1: Background on papillary renal cell carcinoma
Rare Cancer Meta-Analysis, pt.1: Background on papillary renal cell carcinoma administrator 6 Views • 2 years ago

This entry is part one in a series of instructional videos detailing a meta-analysis on eight different human gene expression studies looking at papillary renal cell carcinoma (pRCC). In this installment, I give some background on kidney cancer and detail the different types and subgroups identified in papillary renal cell carcinoma. (I never claimed to be a urologic oncologist, so please forgive any errors in my descriptions of the condition). Please subscribe to this YouTube channel or sign up to my blog (www.bioinfosolutions.com/blog/) to receive notifications on when the next video in the series is posted.

Inspiration for this meta-analysis on papillary kidney cancer came from an upcoming ‘Hackathon’ in May (https://sv.ai/papillary-renal-cell-carcinoma/) that brings together researchers, engineers and computer scientists to try to tackle challenging problems in life sciences. This year they are focusing on papillary renal-cell carcinoma type 1 (p1RCC), a disease that accounts for between 15 to 20% of all kidney cancers. Little is known about the genetic basis of sporadic papillary renal-cell carcinoma, and no effective forms of therapy for advanced disease exist.

Special thanks goes out to the biotech companies Illumina (Correlation Engine and Cohort Analyzer), Partek Inc. (Partek Genomics Suite) and Elsevier (Pathway Studio) for donating their platforms and providing technical assistance for this bioinformatics series.

Showing 1 out of 2